MAGRIT screened over 13,000 patients with resected NSCLC and randomised over 2000 to receive placebo or vaccination with MAGE-A3 immunotherapeutic, comprising recombinant MAGE-A3, a tumour antigen commonly overexpressed in lung cancer, fused to an immunostimulant [36]. The gene discussed is MAGEA3; the disease is lung carcinoma.